Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stockverified

LXEO

Price:

$9.09

Market Cap:

$663.45M

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the trea...[Read more]

Industry

Biotechnology

IPO Date

2023-11-03

Stock Exchange

NASDAQ

Ticker

LXEO

The ROE as of December 2025 (TTM) for Lexeo Therapeutics, Inc. Common Stock (LXEO) is -94.65%

According to Lexeo Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current ROE is -94.65%. This represents a change of 281.27% compared to the average of -24.82% of the last 4 quarters.

Lexeo Therapeutics, Inc. Common Stock (LXEO) Historical ROE (quarterly & annually)

How has LXEO ROE performed in the past?

The mean historical ROE of Lexeo Therapeutics, Inc. Common Stock over the last ten years is 18.79%. The current -94.65% ROE has changed -603.70% with respect to the historical average. Over the past ten years (40 quarters), LXEO's ROE was at its highest in in the December 2022 quarter at 12.91%. The ROE was at its lowest in in the March 2025 quarter at -37.06%.

Quarterly (TTM)
Annual

Average

18.79%

Median

52.48%

Minimum

-84.16%

Maximum

93.07%

Lexeo Therapeutics, Inc. Common Stock (LXEO) ROE by Quarter and Year

Discovering the peaks and valleys of Lexeo Therapeutics, Inc. Common Stock ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 43.91%

Maximum Annual ROE = 93.07%

Minimum Annual Increase = -211.43%

Minimum Annual ROE = -84.16%

Quarterly (TTM)
Annual
YearROEChange
2024-84.16%43.91%
2023-58.48%-211.43%
202252.48%-42.36%
202191.04%-2.18%

Lexeo Therapeutics, Inc. Common Stock (LXEO) Average ROE

How has LXEO ROE performed in the past?

The current ROE of Lexeo Therapeutics, Inc. Common Stock (LXEO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-30.05%

5-year avg

18.79%

10-year avg

18.79%

Lexeo Therapeutics, Inc. Common Stock (LXEO) ROE vs. Peers

How is LXEO’s ROE compared to its peers?

Lexeo Therapeutics, Inc. Common Stock’s ROE is greater than Kyverna Therapeutics, Inc. (-64.93%), greater than Contineum Therapeutics, Inc. Class A Common Stock (-32.33%), greater than Silence Therapeutics plc (-85.88%), greater than Larimar Therapeutics, Inc. (-62.92%), greater than Capricor Therapeutics, Inc. (-62.71%), greater than Mereo BioPharma Group plc (-80.00%), greater than Voyager Therapeutics, Inc. (-48.94%), greater than DBV Technologies S.A. (-287.15%), greater than Amarin Corporation plc (-18.34%), greater than Vanda Pharmaceuticals Inc. (-16.82%),

Build a custom stock screener for Lexeo Therapeutics, Inc. Common Stock (LXEO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexeo Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lexeo Therapeutics, Inc. Common Stock (LXEO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lexeo Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Lexeo Therapeutics, Inc. Common Stock's ROE?

How is the ROE calculated for Lexeo Therapeutics, Inc. Common Stock (LXEO)?

What is the highest ROE for Lexeo Therapeutics, Inc. Common Stock (LXEO)?

What is the 3-year average ROE for Lexeo Therapeutics, Inc. Common Stock (LXEO)?

What is the 5-year average ROE for Lexeo Therapeutics, Inc. Common Stock (LXEO)?

How does the current ROE for Lexeo Therapeutics, Inc. Common Stock (LXEO) compare to its historical average?